Blood tests to predict CAR-T cell treatment results in lymphoma and myeloma
Checks immune cells in adults with lymphoma or myeloma receiving CAR-T therapy.
Plain-language title generated from the registry record
Registry title: Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
Key facts
- Where
- Rouen, FranceSee the site
Where in France
- Centre Henri BecquerelRouen, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Henri Becquerel
- Trial code
- NCT07852377
- Record updated
- 1 October 2026
- Original description
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints. Up to 45 adults with relapsed or refractory B-cell lymphoma or multiple myeloma who are scheduled to receive standard-of-care anti-CD19 or anti-BCMA CAR-T cells will be enrolled. The study will characterize CAR-positive and endogenous CAR-negative T-cell populations and T-cell receptor clonality at apheresis, in the CAR-T product, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These findings will be related to treatment response, toxicities and relapse during 12 months of follow-up. The study hypothesis is that dynamic immunological and molecular characteristics measured along the CAR-T pathway are associated with early response, toxicity and relapse risk.Read full original descriptionShow less
Immunomonitoring and Identification of Predictive Biomarkers of Response, Toxicity and Risk of Relapse After CAR-T Cells in B-cell Lymphomas and Multiple Myeloma
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints. Up to 45 adults with relapsed or refractory B-cell lymphoma or multiple myeloma who are scheduled to receive standard-of-care anti-CD19 or anti-BCMA CAR-T cells will be enrolled. The study will characterize CAR-positive and endogenous CAR-negative T-cell populations and T-cell receptor clonality at apheresis, in the CAR-T product, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These findings will be related to treatment response, toxicities and relapse during 12 months of follow-up. The study hypothesis is that dynamic immunological and molecular characteristics measured along the CAR-T pathway are associated with early response, toxicity and relapse risk.
Inclusion: Age 18 years or older; Relapsed or refractory B-cell lymphoma or multiple myeloma; Indication for anti-CD19 or anti-BCMA CAR-T cell treatment; Signed informed consent; Affiliation to or beneficiary status under a health insurance scheme.
Exclusion: Previous exposure to anti-BCMA bispecific antibodies or need for anti-BCMA bispecific antibodies as bridging therapy before anti-BCMA CAR-T cell administration; Pregnant or breastfeeding; Absence of informed consent; Primary central nervous system lymphoma or primary vitreoretinal lymphoma; Body weight below 30 kg; Protected adult or person deprived of liberty under guardianship or curatorship; Inability to understand the study or comply with study constraints for language, psychological, geographical or other reasons.